These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 11560767)

  • 1. A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons.
    Hwang DY; Carlezon WA; Isacson O; Kim KS
    Hum Gene Ther; 2001 Sep; 12(14):1731-40. PubMed ID: 11560767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically engineered dopamine beta-hydroxylase gene promoters with better PHOX2-binding sites drive significantly enhanced transgene expression in a noradrenergic cell-specific manner.
    Hwang DY; Hwang MM; Kim HS; Kim KS
    Mol Ther; 2005 Jan; 11(1):132-41. PubMed ID: 15585414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area.
    Kügler S; Kilic E; Bähr M
    Gene Ther; 2003 Feb; 10(4):337-47. PubMed ID: 12595892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
    Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
    Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term transgene expression can be mediated in the brain by adenoviral vectors when powerful neuron-specific promoters are used.
    Glover CP; Bienemann AS; Hopton M; Harding TC; Kew JN; Uney JB
    J Gene Med; 2003 Jul; 5(7):554-9. PubMed ID: 12825194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient gene transfer and long-term expression in neurons using a recombinant adenovirus with a neuron-specific promoter.
    Navarro V; Millecamps S; Geoffroy MC; Robert JJ; Valin A; Mallet J; Gal La Salle GL
    Gene Ther; 1999 Nov; 6(11):1884-92. PubMed ID: 10602384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system.
    Koch PE; Guo ZS; Kagawa S; Gu J; Roth JA; Fang B
    Mol Ther; 2001 Mar; 3(3):278-83. PubMed ID: 11273768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting brain stem centers of cardiovascular control using adenoviral vectors: impact of promoters on transgene expression.
    Lonergan T; Teschemacher AG; Hwang DY; Kim KS; Pickering AE; Kasparov S
    Physiol Genomics; 2005 Jan; 20(2):165-72. PubMed ID: 15561757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of viral and mammalian promoters for use in gene delivery to salivary glands.
    Zheng C; Baum BJ
    Mol Ther; 2005 Sep; 12(3):528-36. PubMed ID: 16099414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
    Van Linthout S; Lusky M; Collen D; De Geest B
    Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors.
    Addison CL; Hitt M; Kunsken D; Graham FL
    J Gen Virol; 1997 Jul; 78 ( Pt 7)():1653-61. PubMed ID: 9225042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgene expression in the brain stem effected by intramuscular injection of polyethylenimine/DNA complexes.
    Wang S; Ma N; Gao SJ; Yu H; Leong KW
    Mol Ther; 2001 May; 3(5 Pt 1):658-64. PubMed ID: 11356070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector.
    Arbuthnot PB; Bralet MP; Le Jossic C; Dedieu JF; Perricaudet M; Bréchot C; Ferry N
    Hum Gene Ther; 1996 Aug; 7(13):1503-14. PubMed ID: 8864751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cis-acting elements responsible for dopaminergic neuron-specific expression of zebrafish slc6a3 (dopamine transporter) in vivo are located remote from the transcriptional start site.
    Bai Q; Burton EA
    Neuroscience; 2009 Dec; 164(3):1138-51. PubMed ID: 19755139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo.
    Gerdes CA; Castro MG; Löwenstein PR
    Mol Ther; 2000 Oct; 2(4):330-8. PubMed ID: 11020348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering ex vivo-expanded marrow stromal cells to secrete calcitonin gene-related peptide using adenoviral vector.
    Deng W; Bivalacqua TJ; Chattergoon NN; Jeter JR; Kadowitz PJ
    Stem Cells; 2004; 22(7):1279-91. PubMed ID: 15579646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cochlear function and transgene expression in the guinea pig cochlea, using adenovirus- and adeno-associated virus-directed gene transfer.
    Luebke AE; Foster PK; Muller CD; Peel AL
    Hum Gene Ther; 2001 May; 12(7):773-81. PubMed ID: 11339894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy.
    Sipo I; Hurtado Picó A; Wang X; Eberle J; Petersen I; Weger S; Poller W; Fechner H
    J Mol Med (Berl); 2006 Mar; 84(3):215-25. PubMed ID: 16437213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors.
    Hauser MA; Robinson A; Hartigan-O'Connor D; Williams-Gregory DA; Buskin JN; Apone S; Kirk CJ; Hardy S; Hauschka SD; Chamberlain JS
    Mol Ther; 2000 Jul; 2(1):16-25. PubMed ID: 10899824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector--potential glioblastoma targeting.
    McKie EA; Graham DI; Brown SM
    Gene Ther; 1998 Apr; 5(4):440-50. PubMed ID: 9614567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.